HealthcarePrenatal exposure to phentermine-topiramate lower under safety program

Prenatal exposure to phentermine-topiramate lower under safety program

Prenatal exposure to phentermine-topiramate lower under safety program

Under the Risk Evaluation and Mitigation Strategy (REMS), prenatal exposure to phentermine-topiramate is lower than topiramate and other antiobesity medications (AOMs), according to a study published online March 21 in the Annals of Internal Medicine.

Noting that the U.S. Food and Drug Administration approval of phentermine-topiramate for required a REMS to prevent , Amir Sarayani, Pharm.D., M.P.H., Ph.D., from the University of Florida in Gainesville, and colleagues conducted a involving females aged 12 to 55 years to examine the rate of prenatal exposure, contraceptive use, and pregnancy testing with phentermine-topiramate compared to topiramate or other AOMs. Overall, 156,280 treatment episodes were included.

The researchers found that at treatment initiation, the adjusted prevalence of pregnancy was 0.9 versus 1.6 per 1,000 episodes for phentermine-topiramate versus topiramate (prevalence ratio, 0.54). For phentermine-topiramate versus topiramate, the incidence rate of conception during treatment was 9.1 versus 15.0 per 1,000 person-years (rate ratio, 0.61). Compared with AOMs, for phentermine-topiramate, both outcomes were similarly lower. Prenatal exposure was slightly lower in topiramate versus AOM users. In all cohorts, approximately 20 percent of patients had at least 50 percent of treatment days covered by contraceptives. Furthermore, ≤5 percent of had pregnancy tests before treatment, but this was more common among phentermine-topiramate users.

“Potential exposures were detected, suggesting the need for further clinical vigilance and risk mitigation,” the authors write.

More information:
Amir Sarayani et al, Assessment of the Risk Evaluation and Mitigation Strategy (REMS) for Phentermine–Topiramate to Prevent Exposure During Pregnancy, Annals of Internal Medicine (2023). DOI: 10.7326/M22-1743

Copyright © 2023 HealthDay. All rights reserved.

Prenatal exposure to phentermine-topiramate lower under safety program (2023, March 22)
retrieved 22 March 2023

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.

Original Source Link

Latest News

Jessica Alba Recalls ‘Taking Roles to Survive’ in Her Career – Hollywood Life

Jessica Alba is looking back at the start of her film career. During a new interview with PEOPLE...

Notorious conspiracy theorist Alex Jones’ assets will be sold to pay a $1.5 billion debt to families of the Sandy Hook massacre victims

 A federal judge on Friday ordered the liquidation of conspiracy theorist Alex Jones ′ personal assets but dismissed his company’s...

Bitcoin Crashes To $65,000, Expert Unpacks Drivers Of Crypto Market Bloodbath

The cryptocurrency market has been experiencing a significant downturn, with Bitcoin leading the way by retracing to the...

Raspberry Pi offers London a morsel of hope

This article is an onsite version of our Disrupted Times newsletter. Subscribers can sign up here to get...

The 25 Very Best Gifts for Dad, Picked By a Picky Dad (2024)

Your dad probably isn’t going to complain about any gift you give him. For better or worse, most...

Must Read

- Advertisement -

You might also likeRELATED
Recommended to you